Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515577 | 1.00 | SIGMAR1 (0.53) | SIGMAR1POLBSMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL20148931 | 0.82 | SIGMAR1 (0.55) | SIGMAR1POLBSMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL22574694 | 0.81 | TRPV3 (0.56) | SIGMAR1POLBMAPTTRPV3MEN1 | |
| SCHEMBL11972180 | 0.81 | TRPV3 (0.56) | SIGMAR1POLBMAPTTRPV3MEN1 | |
| SCHEMBL20148924 | 0.81 | SIGMAR1 (0.53) | SIGMAR1POLBSMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL11972186 | 0.81 | TRPV3 (0.56) | SIGMAR1POLBMAPTTRPV3MEN1 | |
| Hydrochloric Acid SCHEMBL11133532 | 0.81 | SIGMAR1 (0.53) | SIGMAR1POLBSMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL765714 | 0.80 | SIGMAR1 (0.68) | SIGMAR1POLBSMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL23792424 | 0.79 | SIGMAR1 (0.52) | SIGMAR1POLBSMN1; SMN2KDM4ECYP3A4 | |
| Hydrochloric Acid SCHEMBL11465429 | 0.79 | SIGMAR1 (0.52) | SIGMAR1POLBSMN1; SMN2KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220306586-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-4036089-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4036082-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9944606-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-8778950-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | disclosed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | SIGMAR1 1021/4885POLB 2796/4885SMN1; SMN2 208/4885 |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | SIGMAR1 1021/4885POLB 2796/4885SMN1; SMN2 208/4885 |
| US-20220306586-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | SIGMAR1 1021/4885POLB 2796/4885SMN1; SMN2 208/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | SIGMAR1 1021/4885POLB 2796/4885SMN1; SMN2 208/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | SIGMAR1 1021/4885POLB 2796/4885SMN1; SMN2 208/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | SIGMAR1 1021/4885POLB 2796/4885SMN1; SMN2 208/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | SIGMAR1 1021/4885POLB 2796/4885SMN1; SMN2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.